or when it's going to be. Let's see - merck has revenue problems with patents expiring - ipsen has problems with increlex - novartis now apparently paying insm $2 billion for partnership (not sure why $2 billion) - what happened to the japan partner? what about the partnership with Ajinomoto? - aetna reviewing iPlex......so what are we going to see first? something has to give with this stock - some kind of partnership has to be right around the corner? before nov 5th conference call?